Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) stock is higher on Thursday, after the company shared preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi ...

Despite improvements in the management of atrial fibrillation, patients with this condition remain at increased risk for cardiovascular complications. It is unclear whether early rhythm-control ...

Please provide your email address to receive an email when new articles are posted on . In patients with recently diagnosed atrial fibrillation and a high comorbidity burden, early rhythm control ...

BOSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The EAST-AFNET 4 trial “clearly shows that early ...

Sophia Antipolis, 27 March 2023: Patients with atrial fibrillation (AF) benefit from early rhythm control therapy. It reduces cardiovascular deaths, strokes, and other adverse outcomes by 20% compared ...

Most patients received flecainide, dronedarone, or amiodarone. At baseline, sinus rhythms were recorded more often in patients in the early rhythm control vs standard care group. Catheter ablation was ...

(UPDATED) Swift initiation of rhythm-control therapy in patients with recently diagnosed atrial fibrillation in the setting of other cardiovascular conditions reduced the risk of CV events as compared ...

Scientists have long wondered when the sense of rhythm first takes shape in the developing brain. It’s been a difficult question to answer not least because studying this in foetuses is almost ...